The Zhitong Finance App learned that ABBV.US (ABBV.US) and Nimble Therapeutics announced that they have reached a final agreement. AbbVie will acquire Nimble and acquire its core assets, including the main project - oral peptide IL-23 receptor (IL-23R) inhibitors, and an innovative oral peptide drug candidate pipeline covering various autoimmune diseases. In addition, AbbVie will also receive Nimble's peptide synthesis, screening and optimization platform, which uses proprietary technology to accelerate the discovery and optimization of peptide drug candidates for multiple targets.

Nimble is a biotechnology company focused on developing oral peptide therapies. With its revolutionary peptide drug discovery and development platform, Nimble is advancing internal pipeline R&D and multiple collaborative projects. The platform integrates large-scale parallel solid phase synthesis, diverse chemical and structural libraries, complex screening methods, and advanced machine learning and computational techniques.

According to the terms of the agreement, AbbVie will pay 0.2 billion US dollars in cash to acquire Nimble upon completion of the transaction, while providing certain medium-term financial support. Additionally, Nimble's shareholders will also have the opportunity to receive additional potential payments after reaching specific development milestones.